1-(4-Methylpyridin-2-yl)propan-2-ol
- $45 - $752
- Product name: 1-(4-Methylpyridin-2-yl)propan-2-ol
- CAS: 937647-99-9
- MF: C9H13NO
- MW: 151.21
- EINECS:
- MDL Number:MFCD08572172
- Synonyms:1-(4-Methylpyridin-2-yl)propan-2-ol;2-Pyridineethanol, α,4-dimethyl-
5 prices
Selected condition:
Brand
- Crysdot
- Matrix Scientific
- TRC
Package
- 10mg
- 50mg
- 100mg
- 500mg
- 5g
- ManufacturerCrysdot
- Product numberCD11008910
- Product description1-(4-Methylpyridin-2-yl)propan-2-ol 97%
- Packaging5g
- Price$752
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number063931
- Product description1-(4-Methylpyridin-2-yl)propan-2-ol
- Packaging500mg
- Price$237
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM571515
- Product description1-(4-methylpyridin-2-yl)propan-2-ol
- Packaging100mg
- Price$130
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM571515
- Product description1-(4-methylpyridin-2-yl)propan-2-ol
- Packaging50mg
- Price$90
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM571515
- Product description1-(4-methylpyridin-2-yl)propan-2-ol
- Packaging10mg
- Price$45
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Crysdot | CD11008910 | 1-(4-Methylpyridin-2-yl)propan-2-ol 97% | 5g | $752 | 2021-12-16 | Buy |
Matrix Scientific | 063931 | 1-(4-Methylpyridin-2-yl)propan-2-ol | 500mg | $237 | 2021-12-16 | Buy |
TRC | M571515 | 1-(4-methylpyridin-2-yl)propan-2-ol | 100mg | $130 | 2021-12-16 | Buy |
TRC | M571515 | 1-(4-methylpyridin-2-yl)propan-2-ol | 50mg | $90 | 2021-12-16 | Buy |
TRC | M571515 | 1-(4-methylpyridin-2-yl)propan-2-ol | 10mg | $45 | 2021-12-16 | Buy |
Properties
Boiling point :253.3±25.0 °C(Predicted)
Density :1.034±0.06 g/cm3(Predicted)
pka :14.59±0.20(Predicted)
Density :1.034±0.06 g/cm3(Predicted)
pka :14.59±0.20(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|